Vandana Abramson
Co-Leader, Breast Cancer Research Program · Vanderbilt University Medical Center
Credentials: · · · · ·
History
- Present
Breast Cancer Research Program · Vanderbilt University Medical Center
- 2004–2006
- 1992–1996
Research
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
New England Journal of Medicine · 2020 · 1,022 citations
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
New England Journal of Medicine · 2019 · 702 citations
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2024 · 560 citations
36 papers
21 papers
- IK
21 papers
- AW
20 papers
18 papers
15 papers
14 papers
14 papers
Grants
- 2026–2031
Improving Outcomes for Patients with Triple-Negative Breast Cancer
National Cancer Institute · R01
PI · $400.3K · Vanderbilt University Medical Center
- 2010–2020
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
National Cancer Institute · U01
PI · $4M · University of Texas at Austin
- 2011–2014
Akt Inhibitor MK-2206 for Breast Cancers with a PIK3CA Mutation and/or PTEN Loss
National Cancer Institute · R21
PI · $552.8K · University of Tx Md Anderson Can Ctr
Clinical trials
- 2025–2033
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Principal investigator · Recruiting · Phase 2
Vandana Abramson
- 2023–2028
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
Principal investigator · Recruiting · Phase 2
Vanderbilt-Ingram Cancer Center
- 2016–2023
Principal investigator · Completed · Phase 1
Vanderbilt-Ingram Cancer Center
- 2015–2022
Principal investigator · Terminated · Phase 1, Phase 2
Vanderbilt-Ingram Cancer Center